

# DIRAS2 is Associated with Adult ADHD, Related Traits, and Co-Morbid Disorders

Andreas Reif<sup>\*1</sup>, T Trang Nguyen<sup>2,24</sup>, Lena Weißflog<sup>3,24</sup>, Christian P Jacob<sup>1,3</sup>, Marcel Romanos<sup>4</sup>, Tobias J Renner<sup>4</sup>, Henriette N Buttenschon<sup>5</sup>, Sarah Kittel-Schneider<sup>1</sup>, Alexandra Gessner<sup>1</sup>, Heike Weber<sup>1</sup>, Maria Neuner<sup>1</sup>, Silke Gross-Lesch<sup>3</sup>, Karin Zamzow<sup>2</sup>, Susanne Kreiker<sup>3,4</sup>, Susanne Walitza<sup>6</sup>, Jobst Meyer<sup>7</sup>, Christine M Freitag<sup>8</sup>, Rosa Bosch<sup>9</sup>, Miquel Casas<sup>9</sup>, Nuria Gómez<sup>9</sup>, Marta Ribasès<sup>9</sup>, Mónica Bayès<sup>10</sup>, Jan K Buitelaar<sup>11</sup>, Lambertus ALM Kiemeneij<sup>12</sup>, JJ Sandra Kooij<sup>13</sup>, Cees C Kan<sup>14</sup>, Martine Hoogman<sup>14</sup>, Stefan Johansson<sup>15,16</sup>, Kaya K Jacobsen<sup>15,16</sup>, Per M Knappskog<sup>15</sup>, Ole B Fasmer<sup>17</sup>, Phil Asherson<sup>18</sup>, Andreas Warnke<sup>4</sup>, Hans-Jörgen Grabe<sup>19</sup>, Jessie Mahler<sup>19</sup>, Alexander Teumer<sup>20</sup>, Henry Völzke<sup>21</sup>, Ole N Mors<sup>5</sup>, Helmut Schäfer<sup>2</sup>, Josep Antoni Ramos-Quiroga<sup>9</sup>, Bru Cormand<sup>22</sup>, Jan Haavik<sup>16,17</sup>, Barbara Franke<sup>14,23</sup> and Klaus-Peter Lesch<sup>3</sup>

<sup>1</sup>Department of Psychiatry, Psychiatric Neurobiology and Bipolar Disorder Program, Psychosomatics and Psychotherapy, University of Würzburg, Würzburg, Germany; <sup>2</sup>Institute of Medical Biometry and Epidemiology, University of Marburg, Marburg, Germany; <sup>3</sup>Department of Psychiatry, ADHD Clinical Research Network, Molecular Psychiatry Laboratory of Translational Neuroscience; Psychosomatics and Psychotherapy, University of Würzburg, Würzburg, Germany; <sup>4</sup>Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Würzburg, Würzburg, Germany; <sup>5</sup>Centre for Psychiatric Research, Aarhus University Hospital, Risskov, Denmark; <sup>6</sup>Department of Child and Adolescent Psychiatry, University of Zuerich, Zuerich, Switzerland; <sup>7</sup>Department of Neurobehavioral Genetics, University of Trier, Institute of Psychobiology, Trier, Germany; <sup>8</sup>Department of Child and Adolescent Psychiatry, Goethe University Frankfurt am Main, Frankfurt, Germany; <sup>9</sup>Department of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain; <sup>10</sup>Centro Nacional de Análisis Genómico (CNAG), Barcelona, Catalonia, Spain; <sup>11</sup>Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behavior, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; <sup>12</sup>Department of Epidemiology, Biostatistics and HTA, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; <sup>13</sup>PsyQ, Psycho-Medical Programs, Program Adult ADHD, The Hague, The Netherlands; <sup>14</sup>Department of Psychiatry, Donders Institute for Brain, Cognition and Behavior, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; <sup>15</sup>Department of Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway; <sup>16</sup>Department of Biomedicine, University of Bergen, Bergen, Norway; <sup>17</sup>Division of Psychiatry, Haukeland University Hospital, Bergen, Norway; <sup>18</sup>MRC Social Genetic Developmental and Psychiatry Centre, Institute of Psychiatry, London, UK; <sup>19</sup>Department of Psychiatry and Psychotherapy, University of Greifswald, Greifswald, Germany; <sup>20</sup>Interfaculty Institute for Genetics and Functional Genomics, University of Greifswald, Greifswald, Germany; <sup>21</sup>Institute for Community Medicine, University of Greifswald, Greifswald, Germany; <sup>22</sup>Departament de Genètica, Facultat de Biologia, Universitat de Barcelona, and CIBER Enfermedades Raras, and Institut de Biomedicina de la Universitat de Barcelona (IBUB), Catalonia, Spain; <sup>23</sup>Department of Human Genetics, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands

Several linkage analyses implicated the chromosome 9q22 region in attention deficit/hyperactivity disorder (ADHD), a neurodevelopmental disease with remarkable persistence into adulthood. This locus contains the brain-expressed GTP-binding RAS-like 2 gene (*DIRAS2*) thought to regulate neurogenesis. As *DIRAS2* is a positional and functional ADHD candidate gene, we conducted an association study in 600 patients suffering from adult ADHD (aADHD) and 420 controls. Replication samples consisted of 1035 aADHD patients and 1381 controls, as well as 166 families with a child affected from childhood ADHD. Given the high degree of co-morbidity with ADHD, we also investigated patients suffering from bipolar disorder (BD) ( $n = 336$ ) or personality disorders (PDs) ( $n = 622$ ). Twelve single-nucleotide polymorphisms (SNPs) covering the structural gene and the transcriptional control region of *DIRAS2* were analyzed. Four SNPs and two haplotype blocks showed evidence of association with ADHD, with nominal  $p$ -values ranging from  $p = 0.006$  to  $p = 0.05$ . In the adult replication samples, we obtained a consistent effect of rs1412005 and of a risk haplotype containing the promoter region ( $p = 0.026$ ). Meta-analysis resulted in a significant common OR of 1.12 ( $p = 0.04$ ) for rs1412005 and confirmed association with the promoter risk haplotype (OR = 1.45,  $p = 0.0003$ ). Subsequent analysis in nuclear families with childhood ADHD again showed an association of the promoter haplotype block ( $p = 0.02$ ). rs1412005 also increased risk toward BD ( $p = 0.026$ ) and cluster B PD ( $p = 0.031$ ). Additional SNPs showed association with personality scores ( $p = 0.008$ – $0.048$ ). Converging lines of evidence implicate genetic variance in the promoter region of *DIRAS2* in the etiology of ADHD and co-morbid impulsive disorders.

Neuropsychopharmacology advance online publication, 13 July 2011; doi:10.1038/npp.2011.120

**Keywords:** adult ADHD; linkage; genome-wide association; ras pathway; association study; bipolar disorder

\*Correspondence: Professor A Reif, Department of Psychiatry, Psychiatric Neurobiology and Bipolar Disorder Program, Department of Psychiatry, Psychosomatics and Psychotherapy, University of Würzburg, Fuchsleinstr. 15, D-97080 Würzburg, Germany, Tel: +49 931 201 76402; Fax: +49 931 201 76403, E-mail: reif\_a@klinik.uni-wuerzburg.de

<sup>24</sup>These authors contributed equally to this work.

Received 27 November 2010; revised 11 April 2011; accepted 24 May 2011

## INTRODUCTION

Attention deficit/hyperactivity disorder (ADHD) is a prevalent psychiatric condition in childhood associated with substantial impairment. In up to 30% of all affected cases, the disorder persists into adulthood (adult ADHD, aADHD; Faraone *et al*, 2000), although the core symptoms become less prominent, as adaptive mechanisms interfere with the presentation of the disease and as co-morbid conditions modify or even dominate the clinical picture. The latter include substance use disorders, affective, and personality disorders (PDs) (Jacob *et al*, 2007). Furthermore, there is accumulating evidence for neurobiological overlap with bipolar disorder (BD), with a high percentage of aADHD patients also suffering from BD (Klassen *et al*, 2010; Wingo and Ghaemi, 2007) and even more from bipolar symptoms on the dimensional level (Halmoy *et al*, 2010). Conversely, approximately 10% of BD patients suffer from ADHD, suggesting a subgroup of patients where pathologies overlap and presumably risk genes are shared (Nierenberg *et al*, 2005; Tamam *et al*, 2008). aADHD patients feature a distinct personality profile, with increased scores in the personality domain *Neuroticism* as measured with the NEO PI-R (Costa and McCrae, 1992), while *Conscientiousness*, *Extraversion*, and *Openness* are decreased (Jacob *et al*, 2007). Similarly, personality assessment using the TPQ (Cloninger *et al*, 1993) reveals that *Novelty Seeking* and *Harm Avoidance* are increased in aADHD patients (Jacob *et al*, 2007). Taken together, the clinical appearance of aADHD represents a complex clinical phenotype. ADHD in children (cADHD) was repeatedly shown to feature a strong genetic component, and a meta-analysis of 20 studies provided a heritability index of 0.76 (Faraone *et al*, 2005). However, despite this considerable heritability, only a few risk genes with small effects have been identified. This might be due to the facts that cADHD (a) is a heterogeneous clinical condition (with the risk of phenocopies), (b) might feature substantial ethnic background effects, and (c) is a genetically complex disorder with common variants conveying low risk (Franke *et al*, 2009) as well as individually rare variants with variable penetrance conveying high risk (Becker and Knapp, 2004; Lesch *et al*, 2011; Williams *et al*, 2011). aADHD has come into the focus of genetic research more recently, but has also been shown to have a genetic basis (IMpACT Collaboration, submitted). Molecular genetic findings are even more sparse; this might partly be due to the fact that not only risk variants causing disease as such come into play, but also genes modifying the developmental trajectory of the disorder—that is, persistence into adulthood (eg, *SLC6A3*; (Franke *et al*, 2010)—may be of importance.

To overcome the problematic issues coming along with candidate gene studies, genome-wide approaches were increasingly used in the last years. These include genome-wide linkage analyses, eight of which have been published so far; seven of these were included in a meta-analysis (Zhou *et al*, 2008). Furthermore, genome-wide association studies (GWAS) were employed to find new risk genes (Franke *et al*, 2009; Neale *et al*, 2010a,b). We have previously reported on a pooled GWAS in aADHD (Lesch *et al*, 2008), where two single-nucleotide polymorphisms (SNPs) in the top 500 localized to the intergenic region

between *DIRAS2* and *SYK* on chromosome 9q22.2. The *DIRAS2*-*SYK* locus is also supported by two linkage scans, one of which was performed in individuals from the same catchment population as the aADHD GWAS (Romanos *et al*, 2008), while the other was conducted in the United Kingdom (Asherson *et al*, 2008). Further interest in this region comes from a pooled GWAS in PD, where *SYK* was the number 11 top-locus for cluster B PD (in preparation). Thus, three independent and hypothesis-free studies provide converging evidence that this locus might contribute to the genetic risk for disorders of cognitive control featuring increased impulsivity. *DIRAS2* is strongly expressed in the brain, while *SYK* is preferentially expressed in peripheral tissues, making *DIRAS2* the prime candidate gene at this locus. Intriguingly, in a recent GWAS on cognitive performance of the aging brain, *DIRAS2* was associated ( $p = 8 \times 10^{-6}$ ) with performance in the Boston naming test arguing for a role of *DIRAS2* in cognitive processes (Seshadri *et al*, 2007).

These findings prompted us to conduct a study using large discovery and replication aADHD samples to assess the genetic relevance of *DIRAS2* for aADHD. In addition, we attempted generalization of the findings to cADHD and to related disorders of impulsivity. As the discovery samples also were assessed for personality factors, we were also able to test the influence of *DIRAS2* on impulsivity-related traits, which might be considered an intermediate phenotype of ADHD.

## MATERIALS AND METHODS

### Samples

**Discovery sample: aADHD sample.** The sample was previously described in greater detail (Franke *et al*, 2010; Jacob *et al*, 2007). Briefly, 600 patients were extensively examined using a semi-structured interview as well as by applying the SCID-I and SCID-II. Personality assessment was done using NEO PI-R and TPQ. Eligibility criteria for the study were aADHD according to the diagnostic criteria of DSM-IV (Diagnostic and Statistical Manual for Mental Disorders), onset before the age of 7 years, life-long persistence, current diagnosis, and age at recruitment between 18 and 65 years. Exclusion criteria were a current diagnosis of drug/alcohol abuse/dependence (before detoxification/withdrawal), or a lifetime diagnosis of BD, schizophrenia, and mental retardation. A more detailed sample description including the used rating scales can be obtained from Supplementary Methods. The control group was recruited from the Lower Franconia area in Germany and consisted of 420 healthy volunteers. This sample of volunteers was also used as a control for the association analysis for PD and BD.

**Family-based childhood ADHD sample.** Detailed information on the sample was reported previously (Renner *et al*, 2008). Briefly, total sample size was 166 families, of whom 109 were trios, 42 quartets, and 15 were multi-sibling families. We recruited families with at least one child affected by ADHD, combined type according to DSM-IV as diagnosed by a structured interview with the parents

(KIDDIE-SADS), parent and teacher questionnaires and direct clinical observation. The index child was aged 8 years or above. Exclusion criteria were IQ below 80, co-morbid autistic or somatic disorders, primary affective disorders including BD, Tourette's syndrome, psychotic, or other severe primary psychiatric disorders.

**IMpACT aADHD samples.** The aADHD replication samples have been described in detail elsewhere (Franke *et al*, 2010). The total sample included 1035 aADHD patients and 1381 controls and originated from the Netherlands (285 patients and 508 controls), Norway (497 cases and 562 controls), Spain (253 patients and 311 controls), and was made available within the framework of the IMpACT consortium. All patients were evaluated by experienced psychiatrists and diagnosed with persistent ADHD according to DSM-IV criteria and also using standardized rating scales. Consensus eligibility criteria for this study across all study sites were a diagnosis of ADHD according to the diagnostic criteria of DSM-IV, onset before the age of 7 years by retrospective diagnosis (which was confirmed by a family member, wherever possible), life-long persistence and current diagnosis. Further information on the samples as well as used rating scales can be obtained from Supplementary Methods.

**PD sample.** This sample has been described in detail previously (Jacob *et al*, 2005). A total of 622 inpatients and outpatients of the Department of Psychiatry and Psychotherapy, University of Würzburg with PDs according to DSM-IV criteria participated in the study. Patients were drawn from the general population of hospital patients; every patient with a clinical diagnosis of PD treated in the department from 2000 to 2004 was approached and asked to participate in the study. Inclusion criteria were PD according to DSM-IV (antisocial, histrionic, borderline, narcissistic, avoidant, dependent, and obsessive-compulsive PD) and age between 18 and 60 years. Exclusion criteria were medical conditions and lifetime diagnosis of schizophrenia or other psychotic disorders. The SCID-II was used to diagnose PDs, and PDs were allocated to cluster B and C operationalized as follows: cluster B (77%) (dramatic-emotional) encompasses antisocial, borderline, histrionic, and narcissistic PDs. Cluster C (37%) (anxious-fearful) includes avoidant, dependent, and obsessive-compulsive PDs. Furthermore, co-morbid axis-I disorders were assessed using the SCID-I as well as extensive clinical interview. Thereby, a lifetime diagnosis of BD (type I and II) was established in 17 of the 622 PD patients (2.7%). The assessment of the PDs, including all psychometric testing, was performed by a single experienced psychiatrist (CPJ).

**BD sample.** This study investigated a sample described previously in detail (Scholz *et al*, 2010). This sample consisted of 170 unrelated bipolar patients (mean age  $53 \pm 14$  years, 68% female), from the German Lower Franconia area for whom an ICD-10 diagnosis was established by means of an extensive, semi-structured interview analogous to the AMDP interview (AMDP, 2000) carried out by two experienced psychiatrists at the University of Würzburg. Furthermore, the OPCRIT system was used in these patients (McGuffin *et al*, 1991). A further 166 unrelated bipolar patients (mean age  $43.0 \pm 11.5$  years,

49% female), were ascertained according to ICD-10 diagnostic criteria for research (DCR) by means of a semi-structured interview (SCAN ver. 2.1.) at the Center for Psychiatric Research, Århus University Hospital, giving a total number of 336 patients suffering from BD. Co-morbidity data for BD with aADHD could not be obtained as these patients were ascertained during acute disease episodes where it is not possible to reliably establish a diagnosis of aADHD. None of the subjects showed significant neurological co-morbidity, epilepsy, mental retardation, or other somatic disorders suggesting organic psychosis. Patients with substance-induced disorders were excluded.

### *In Silico* Replication in the SHIP GWAS

Data from the Study of Health in Pomerania (SHIP) were used (Grabe *et al*, 2005). The target population comprises adult German residents (20–79 years) in a northeastern German population of 212 157 individuals. The net sample comprised 6267 eligible subjects, of which 1859 consecutively recruited subjects were eligible for the present analyses. The assessment of personality traits was performed with the NEO-FFI-30 (Korner *et al*, 2008). The sample was genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0. As most of the *DIRAS2* SNPs genotyped in the discovery sample (Table 1) were not captured, genotype data were derived from standard imputation procedures using the software IMPUTE v0.5.0 based on HapMap II.

All cases and controls of the above samples were of self-reported German (or Danish, respectively) ancestry. The study was approved by the respective ethics committees of the participating centers and complied with the latest version of the Declaration of Helsinki. Written informed consent was provided by all participants.

### Marker Selection and Genotyping

In all, 14 SNPs were selected, which tagged the promoter region, the 5' and 3' UTRs as well as the transcribed exon of the *DIRAS2* gene, spanning a chromosomal region of 33 kb. Marker selection was performed using the Tagger algorithm (parameter: pair-wise tagging only,  $r^2$  threshold = 0.8, minor allele frequency (MAF) above 5%) as implemented in HaploView ([www.broad.mit.edu/mpg/haploview](http://www.broad.mit.edu/mpg/haploview)) (Figure 1; the haplotype structure was comparable in each sample). SNPs were genotyped using the Sequenom MassArray system (Sequenom, San Diego, CA) coupled to a Bruker Autoflex mass spectrometer (Bruker Daltonics, Bremen, Germany) according to the manufacturer's instructions. PCR was performed using iPLEX chemistry as recommended in the MassArray iPLEX standard operating procedure. Primer sequences can be obtained on request. rs12350590, located proximal of the *DIRAS2* gene, and rs9695432 in intron 1, were excluded from further analyses because of MAF < 0.01 in the discovery sample.

### Statistical Analysis

For all samples, we analyzed only SNPs passing quality check which was defined by MAF > 0.01, call rate > 90% and

**Table 1** General SNP Information with Minor Allele Frequency (%)


SNP NR	SNP ID	Physical position	Region	Major allele	Minor allele	German aADHD		German cADHD		Spanish aADHD		Dutch aADHD		Norwegian aADHD		Bipolar disorder		Personality disorder	
						Cases n = 600	Controls n = 420	Parents n = 166	Offspring n = 244	Cases n = 253	Controls n = 311	Cases n = 285	Controls n = 508	Cases n = 497	Controls n = 562	Cases n = 336	Cases n = 672		
1	rs7868194	92409604	3' region	A	G	43.2	47.0	45.4	45.2	46.7	50.3	48.4	47.9	45.9	46.9	43.4	47.4		
2 <sup>a</sup>	rs12350590	92410160	3' region	C	G	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
3	rs7854469	92412049	3' UTR	T	A	7.5	10.2	9.8	8.1	14.9	11.6	11.4	8.9	9.0	8.9	9.9	9.1	9.1	9.1
4	rs1542479	92412869	3' UTR	G	A	4.3	2.8	3.7	2.8	3.6	5.4	4.6	4.4	4.7	5.2	3.5	3.5	3.5	3.5
5	rs16906711	92413098	3' UTR	C	G	2.9	1.5	2.2	1.5	2.8	3.4	2.5	2.5	2.3	2.3	2.0	3.0	3.0	3.0
6	rs690111	92417110	Intron 1	G	T	26.1	24.1	29.3	29.9	24.7	21.8	26.3	26.6	25.8	26.5	27.3	24.3	24.3	24.3
7	rs1017753	92417721	Intron 1	C	T	47.7	50.1	49.5	49.8	49.8	45.6	47.8	48.7	49.0	48.2	47.4	49.7	49.7	49.7
8 <sup>a</sup>	rs9695432	92417994	Intron 1	G	A	0.5	1.5	0.4	0.5	1.6	0.7	1.8	0.9	1.5	0.6	0.5	0.9	0.9	0.9
9	rs1331503	92442337	Intron 1	T	A	37.8	32.3	32.1	33.4	35.9	35.7	34.1	32.9	33.9	33.1	35.7	36.4	36.4	36.4
10	rs2297354	92444160	Intron 1	C	G	2.0	1.2	1.3	1.1	1.2	0.7	1.6	0.7	2.1	2.6	1.5	1.0	1.0	1.0
11	rs1331504	92445648	Intron 1	G	C	8.7	8.4	6.9	6.8	7.8	8.3	7.1	6.4	7.4	6.6	6.7	8.1	8.1	8.1
12	rs7848810	92447678	Promoter	C	A	28.2	31.5	30.3	28.0	33.1	29.7	28.5	28.3	22.2	24.3	28.0	28.4	28.4	28.4
13	rs1412005	92448981	Promoter	G	T	27.9	23.0	26.1	25.7	26.3	23.9	26.4	25.2	26.4	26.0	28.2	27.6	27.6	27.6
14	rs689687	92450021	Promoter	T	C	19.4	18.5	16.1	13.7	19.0	19.8	17.0	17.2	17.3	19.0	20.3	19.0	19.0	19.0

<sup>a</sup>SNPs were excluded from further analyses because of low MAF (<0.01).

$p$ -value of  $\chi^2$  test for Hardy–Weinberg equilibrium > 0.01 in controls or parents. Inconsistent genotypes in the family sample were revealed and removed by means of PedCheck (O’Connell and Weeks, 1998). Generalized linear models (GLM) implemented in the R function glm() were carried out to test for an association between SNP genotype as independent variable and a trait of interest as dependent variable (binary: ADHD, bipolar, cluster B and C PD; quantitative: NEO-PI R (Neuroticism, Extraversion, Openness, Agreeableness, and Conscientiousness) and TPQ (Novelty Seeking, Harm Avoidance, and Reward Dependence)). Binomial logit link or Gaussian identity link was used for binary or quantitative traits, respectively. We also performed Fisher’s exact test in order to assure the asymptotic test results of glm(). Family-based association analysis was carried out using pedigree disequilibrium test (sumPDT, Martin et al, 2000) to assess whether an allele is more frequently transmitted to affected offspring by taking relationships between the offspring into account.

We used the omnibus test implemented in famhap (10 000 simulations; (Becker and Knapp, 2004) to test the global hypothesis that association with ADHD may be contributed by at least one of the estimated haplotypes. The LD blocks were defined by pairwise  $D' > 0.65$  assessed using Haploview. After the haplotype ACGCTT from block 2 (consisting of SNPs rs1331503, rs2297354, rs1331504, rs7848810, rs1412005, and rs689687) was identified as the sole haplotype consistently increasing risk across all samples, a haplotype-specific association test using Unphased (Dudbridge, 2008) was carried out.

For the meta-analysis, we assumed a common effect of the rs1412005 T allele and the ACGCTT haplotype on the risk for



**Figure 1** LD plot of DIRAS2 aligned to the gene structure and the significant SNPs from all samples. Please note that the LD plot is not exactly matched to the SNPs, as precise scaling is not possible: rs9695432 is the last SNP of block 1 while rs1331503 is the first SNP of block 2. rs16906711 is associated with aADHD, cluster C PD, cluster B PD, and Harm Avoidance in PD; rs9695432 with aADHD and personality domains; rs1331503 with aADHD and personality domains; rs2297354 with aADHD and personality domains; rs7848810 with aADHD, cluster B PD, BD, and personality domains; and rs1412005 with aADHD and personality domains.

ADHD, as there was no effect heterogeneity across all four considered aADHD case-control samples ( $p$ -value = 0.43 and 0.29, respectively, Woolf's test for heterogeneity, obtained with the R function `meta.MH()`). A joint analysis assessing the common OR was done by means of GLM described above, adjusted for fixed country effect. This approach was also applied to the total data set including all patients (aADHD, bipolar, and PDs) and controls in order to estimate the cross disorder effects of *DIRAS2* SNPs.

Unless otherwise specified,  $p$ -values are two-sided  $p$ -values unadjusted for multiple testing. The significance level was set to 0.05. Our study primarily aimed at detecting ADHD-associated SNP variants of *DIRAS2*, whereas analyses for other traits were exploratory. Therefore, we used the Bonferroni method to calculate  $p$ -values adjusted for testing multiple SNPs and haplotypes for association with ADHD.

Power calculations were performed under a two-sided nominal significance level of 0.05 using QUANTO version 1.0 (<http://hydra.usc.edu/gxe>). We assumed an effect size between 1.1 and 1.5 for the rs1412005 T allele and between 1.3 and 3.0 for the ACGCTT haplotype. By given disease prevalence of 5%, we computed the power to detect these variants in the replication sample consisting of 1035 aADHD patients and 1381 controls from IMPACT, under a frequency of 25% and 5% for the rs1412005 T allele and the ACGCTT haplotype, respectively. All assumptions nearly corresponded with nominal 95% confidence intervals and frequencies estimated from the discovery sample.

## RESULTS

### Association of *DIRAS2* with aADHD

Table 1 displays information about functional and physical location of each SNP in/near *DIRAS2*. In the discovery sample of 600 aADHD patients and 420 controls from Germany, 4 out of 12 investigated SNPs had  $p < 0.05$  in the association test with aADHD (Table 2). An empirical test at the gene level for association of at last one of 12 SNPs yielded a  $p = 0.0127$  (10 000 permutations). Upon haplotype

testing, both LD blocks (Figure 1) showed evidence of association with nominally significant  $p$ -values ( $p = 0.006$  for block 1 and  $p = 0.033$  for block 2).

Replication in 1035 aADHD patients and 1381 controls from IMPACT did not show any significant SNP association (all  $p > 0.07$ ; Table 2). Also for each individual country, we found neither an association on the single marker ( $p > 0.1$ , Supplementary Table 1) nor on the haplotype level ( $p > 0.09$ ). However, consistency of the effect size estimates was observed indicating increased aADHD risk for carriers of the A allele of rs1331503, the T allele of rs1412005, and the haplotype ACGCTT from block 2 (consisting of SNPs rs1331503, rs2297354, rs1331504, rs7848810, rs1412005, and rs689687; Table 3) across the four samples. Association testing for this specific haplotype provided a significant result in the initial sample from Germany ( $p = 0.0006$ ), which replicated in the additional independent combined samples from IMPACT ( $p = 0.026$ ). To further explore the association of *DIRAS2* with aADHD, we performed five meta-analyses, for the best four SNPs of the discovery sample (rs7854469, rs16906711, rs1331503, and rs1412005) and for the risk haplotype ACGCTT, in all 1635 aADHD cases and 1801 controls from Germany, the Netherlands, Spain, and Norway taking population strata into account. A  $p = 0.04$  was found for the rs1412005 T allele in the association test with aADHD ( $p$ -value adjusted for five tests: 0.22; OR = 1.12, 95% CI: 1.00–1.25; Figure 2). The risk haplotype ACGCTT (9.0% in cases and 6.5% in controls) was associated with an increased risk for aADHD, and this effect was statistically significant even after adjusting for multiple testing ( $p = 0.00028$ ,  $p$ -value adjusted for five tests: 0.001, OR = 1.45, 95% CI: 1.19–1.77; Figure 3). This haplotype contains the T allele of SNP rs1412005.

### *DIRAS2* and Childhood ADHD

In order to extend our findings for *DIRAS2* to cADHD, we also analyzed 166 independent nuclear families with offspring affected by cADHD. The rs1412005 T allele was

**Table 2** SNP Results of Case–Control-Based Association Analyses for aADHD

SNP NR	SNP ID	German discovery sample			IMPACT replication sample			Pooled data		
		$p$ -Value	OR (allele)	95%-CI	$p$ -Value	OR (allele)	95%-CI	$p$ -Value	OR (allele)	95%-CI
1	rs7868194	0.0880	1.18 (A)	0.98–1.42	0.4395	1.05 (A)	0.93–1.18	0.1174	1.08 (A)	0.98–1.20
3	rs7854469	<b>0.0394</b>	1.40 (T)	1.02–1.93	0.0720	1.19 (A)	0.98–1.43	0.6023	1.04 (A)	0.89–1.23
4	rs1542479	0.0905	1.55 (A)	0.93–2.59	0.3378	1.15 (G)	0.87–1.51	0.9958	1.00 (A)	0.79–1.27
5	rs16906711	<b>0.0453</b>	1.97 (G)	1.01–3.81	0.7288	1.07 (C)	0.74–1.55	0.4271	1.14 (G)	0.83–1.55
6	rs690111	0.3392	1.11 (T)	0.90–1.37	0.8043	1.02 (T)	0.89–1.16	0.4684	1.04 (T)	0.93–1.17
7	rs1017753	0.2741	1.11 (C)	0.92–1.33	0.4749	1.04 (C)	0.93–1.17	0.2353	1.06 (C)	0.96–1.17
9	rs1331503	<b>0.0125</b>	1.27 (A)	1.05–1.54	0.5812	1.03 (A)	0.92–1.17	0.0678	1.10 (A)	0.99–1.22
10	rs2297354	0.2101	1.62 (G)	0.76–3.44	0.6599	1.11 (G)	0.70–1.77	0.2880	1.24 (G)	0.84–1.82
11	rs1331504	0.8241	1.04 (C)	0.75–1.44	0.5302	1.07 (C)	0.86–1.34	0.5195	1.06 (C)	0.88–1.28
12	rs7848810	0.1244	1.17 (C)	0.96–1.42	0.9898	1.00 (A)	0.88–1.14	0.3942	1.05 (C)	0.94–1.17
13	rs1412005	<b>0.0182</b>	1.29 (T)	1.04–1.58	0.3785	1.06 (T)	0.93–1.21	<b>0.0437</b>	1.12 (T)	1.00–1.25
14	rs689687	0.6039	1.07 (C)	0.84–1.36	0.3791	1.07 (T)	0.92–1.24	0.6344	1.03 (T)	0.91–1.17

Nominal  $p$ -values  $< 0.05$  are in bold print.

**Table 3** Association Analysis of the ACGCTT Haplotype<sup>a</sup> for the Studied aADHD Case–Control Samples

Sample	Frequency: N (%)		Association test		
	Cases	Controls	p-Value	OR	95%-CI
Germany	89 (8.94)	30 (4.57)	0.0006	2.05	1.34–3.14
The Netherlands	46 (9.54)	66 (7.45)	0.1815	1.31	0.88–1.94
Spain	28 (6.48)	25 (4.46)	0.1815	1.48	0.85–2.58
Norway	76 (10.08)	78 (8.35)	0.2213	1.23	0.88–1.71

<sup>a</sup>Haplotype consists of SNPs rs1331503, rs2297354, rs1331504, rs7848810, rs1412005, and rs689687.



not significantly over-transmitted ( $p = 0.65$ ), but the C allele of the neighboring SNP rs7848810—also a promoter SNP—was ( $p = 0.046$ , transmission rate: 53%; Table 4). Haplotype analysis provided evidence of significant association of the haplotype 2 ( $p = 0.0231$ ) with a  $p$ -value for the specific haplotype ACGCTT slightly exceeding 0.05 ( $p = 0.0692$ , frequency among transmitted vs non-transmitted haplotypes: 11% vs 6.5%, OR = 2.01, 95% CI: 0.80–5.00). rs7848810 was also associated with co-morbid dyslexia ( $p = 0.015$ ).

### Expanding the Phenotype: Association of DIRAS2 with PDs and BD

To examine whether *DIRAS2* is specifically linked to ADHD or whether the association generalizes to disorders sharing the feature of impulsivity and emotional instability (independent of co-morbidity with ADHD), we performed association analyses in two further independent samples: patients suffering from PDs and BD. We found nominal evidence of association of rs1412005, the SNP implicated in aADHD (see above), with cluster B PD ( $p = 0.031$ ) and BD ( $p = 0.026$ ). The OR of the T allele for both disorders was estimated at around 1.26 (Table 5). The T allele also tended toward increasing risk for cluster C PD ( $p = 0.086$ ) with the same OR estimate of 1.26.

### DIRAS2 Relates to Personality Factors Linked to aADHD

The Würzburg aADHD and PD samples had also been tested for personality dimensions, as assessed by two questionnaires (NEO-PI R: *Neuroticism*, *Extraversion*, *Openness to Experience*, *Agreeableness*, and *Conscientiousness*; and TPQ: *Novelty Seeking*, *Harm Avoidance*, and *Reward Dependence*). Given the association of *DIRAS2* variants with PDs (see above), and considering that aADHD goes along with a distinct personality profile (Jacob et al, 2007), we additionally investigated whether personality scores may also be affected by *DIRAS2* variants. Table 6 represents all nominally significant association results. In the aADHD sample, associations with  $p < 0.05$  were found for *Neuroticism*, *Extraversion*, *Agreeableness*, *Conscientiousness*, and *Harm Avoidance* ( $p$ -values between 0.002 and 0.033). The three SNPs rs1331503, rs1412005, and rs689687, which were associated with these personality traits, are located in haplotype block 2 and the transcriptional control region of the gene. In the PD sample, nominal evidence of

**Figure 2** Forest plot of the rs1412005 T allele for the aADHD case–control association study.**Figure 3** Forest plot of the ACGCTT haplotype for the aADHD case–control association study.

association was found for *Extraversion*, *Agreeableness*, *Conscientiousness*, *Novelty Seeking*, and *Harm Avoidance* ( $p$ -values between 0.008 and 0.040; Table 6). In comparison with the aADHD sample, different SNPs showed association in this sample and almost all of them are located in the haplotype block 1. However, rs7854469 was associated both with aADHD (see above) and the ADHD-relevant personality trait *Extraversion* ( $p = 0.0075$ , Table 6) in PD. Also the aADHD-associated SNP rs7848810 was associated with TPQ *Novelty Seeking* ( $p = 0.0396$ , Table 6) and NEO PI-R *Conscientiousness* ( $p = 0.0123$ , Table 6) in the PD sample.

Owing to the pitfalls of multiple testing, inevitable in personality genetics, replication attempts are paramount. We have thus analyzed 1859 subjects from a general population study (SHIP) who have been examined for personality factors; apart from rs7848810, SNPs had to be

imputed from data acquired on the Affymetrix Human SNP Array 6.0 platform. In doing so, rs16906711 was found to be associated with NEO PI-R *Neuroticism* ( $p = 0.046$ , Supplementary Table 2), and rs1331504 with NEO PI-R *Conscientiousness* ( $p = 0.002$ , Supplementary Table 2).

## DISCUSSION

On the basis of the results of four hypothesis-free approaches converging on the chromosomal locus 9q22.2—two linkage scans for cADHD, a pooled GWAS of aADHD, and a pooled GWAS of PD—we examined the *DIRAS2* gene by genotyping 14 markers, selected to tag the promoter region, the 5' and 3' UTRs and the only coding exon of the gene, in a total of seven independent patient samples. ADHD findings replicated across aADHD samples, with meta-analytic treatment implicating the ACGCTT haplotype (which spans the regulatory region of *DIRAS2*) and one of the SNPs contributing to this haplotype (rs1412005, T allele), and generalized to ADHD in childhood. However, after correction for multiple testing, only the association of the haplotype remained significant arguing that the association of *DIRAS2* with ADHD most likely is not due to one of the examined single markers but rather to a variant segregating with this risk haplotype. Furthermore, expanding the phenotype to impulsivity disorders and impulsivity-related traits pointed toward a role for *DIRAS2*. Although two of the associated SNPs are located in the 3' UTR and potentially involved in expression regulation (rs7854469 and rs16906711), two others (rs7848810 and rs1412005) were located upstream of the transcription start site (Figure 1). Scanning of the transcriptional control region SNPs for putative overlapping transcription factor-binding motifs revealed that the sequence carrying the major allele of rs7848810 contained predicted response elements for PBX1 and for the PBX-HOXA9 dimer. PBX1 is known for its developmental regulation of neuropeptide Y expression (Mayer et al,

**Table 4** Results of Family-Based Association Analysis for cADHD

SNP NR	SNP ID	Over-transmission		PDT $p$ -Value
		Allele	Rate (%)	
1	rs7868194	G	50.9	0.6507
3	rs7854469	T	50.8	0.2059
4	rs1542479	G	50.5	0.1779
5	rs16906711	C	50.2	0.3711
6	rs690111	G	50.9	0.4982
7	rs1017753	T	50.9	0.6911
9	rs1331503	A	52.2	0.4245
10	rs2297354	C	50.3	0.2253
11	rs1331504	G	50.1	0.8997
12	rs7848810	C	52.8	<b>0.0463</b>
13	rs1412005	T	51.4	0.6565
14	rs689687	T	51.3	0.1456 <sup>a</sup>

<sup>a</sup>Call rate = 77%.

Nominal  $p$ -values <0.05 is in bold print.

**Table 5** Results of Case–Control Association Analysis for Co-Morbid Bipolar Disorder and Personality Disorders

SNP NR	SNP ID	Bipolar			Cluster B			Cluster C		
		$p$ -Value	OR (allele)	95%-CI	$p$ -Value	OR (allele)	95%-CI	$p$ -Value	OR (allele)	95%-CI
1	rs7868194	0.1794	1.15 (A)	0.94–1.42	0.9272	1.01 (G)	0.84–1.22	0.3893	1.11 (G)	0.88–1.39
3	rs7854469	0.8687	1.03 (T)	0.73–1.44	0.0868	1.35 (T)	0.96–1.91	0.5588	1.12 (A)	0.77–1.63
4	rs1542479	0.4349	1.26 (A)	0.70–2.26	0.5663	1.17 (A)	0.68–2.00	0.3782	1.34 (A)	0.70–2.56
5	rs16906711	0.4935	1.32 (G)	0.59–2.94	<b>0.0454<sup>a</sup></b>	1.95 (G)	1.01–3.75	<b>0.0220<sup>a</sup></b>	2.33 (G)	1.13–4.80
6	rs690111	0.1752	1.18 (T)	0.93–1.50	0.7622	1.03 (T)	0.83–1.29	0.8047	1.03 (G)	0.79–1.36
7	rs1017753	0.2906	1.12 (C)	0.91–1.38	0.9950	1.00 (C)	0.83–1.21	0.3930	1.10 (T)	0.88–1.39
9	rs1331503	0.1923	1.16 (A)	0.93–1.44	0.1416	1.16 (A)	0.95–1.42	0.1950	1.18 (A)	0.92–1.50
10	rs2297354	0.6345	1.24 (G)	0.51–3.02	0.5963	1.28 (C)	0.51–3.18	0.8929	1.07 (G)	0.38–2.99
11	rs1331504	0.2404	1.27 (G)	0.85–1.89	0.6503	1.08 (G)	0.77–1.53	0.5419	1.14 (G)	0.74–1.76
12	rs7848810	0.1645	1.17 (C)	0.94–1.47	0.1065	1.18 (C)	0.96–1.46	0.7176	1.05 (C)	0.82–1.34
13	rs1412005	<b>0.0256</b>	1.32 (T)	1.03–1.67	<b>0.0305</b>	1.27 (T)	1.02–1.59	0.0855	1.26 (T)	0.97–1.64
14	rs689687	0.3988	1.12 (C)	0.86–1.47	0.7428	1.04 (C)	0.81–1.34	0.8141	1.04 (C)	0.77–1.40

<sup>a</sup> $p$ HWE = 0.001.

Nominal  $p$ -values <0.05 are in bold print.

**Table 6** Nominally Significant Results of Association Analysis for Quantitative Personality Traits

SNP NR	SNP ID	Personality trait	aADHD cases			PD patients		
			p-Value	Beta (allele)	SE	p-Value	Beta (allele)	SE
9	rs1331503	Neuroticism	<b>0.0241</b>	3.51 (A)	1.55	0.3113	1.72 (A)	1.70
14	rs689687	Neuroticism	<b>0.0327</b>	4.14 (C)	1.93	0.5747	1.15 (C)	2.05
3	rs7854469	Extraversion	0.4172	2.07 (A)	2.55	<b>0.0075</b>	6.32 (T)	2.36
9	rs1331503	Extraversion	<b>0.0065</b>	3.68 (T)	1.35	0.6695	0.59 (T)	1.38
13	rs1412005	Extraversion	<b>0.0088</b>	3.83 (G)	1.46	0.7600	0.44 (T)	1.42
3	rs7854469	Agreeableness	0.8963	0.26 (T)	1.96	<b>0.0116</b>	4.24 (A)	1.67
10	rs2297354	Agreeableness	0.2065	4.78 (C)	3.78	<b>0.0288</b>	10.03 (C)	4.57
14	rs689687	Agreeableness	<b>0.0284</b>	2.80 (C)	1.28	0.2645	1.28 (T)	1.15
6	rs690111	Conscientiousness	0.9152	0.17 (T)	1.60	<b>0.0448</b>	2.87 (T)	1.43
9	rs1331503	Conscientiousness	<b>0.0173</b>	3.24 (T)	1.36	0.1876	1.77 (T)	1.34
12	rs7848810	Conscientiousness	0.9051	0.18 (C)	1.52	<b>0.0123</b>	3.49 (A)	1.39
13	rs1412005	Conscientiousness	<b>0.0135</b>	3.61 (G)	1.46	0.1013	2.26 (G)	1.38
14	rs689687	Conscientiousness	<b>0.0043</b>	4.84 (T)	1.69	0.1166	2.50 (T)	1.59
3	rs7854469	Novelty seeking	0.8075	0.16 (A)	0.65	<b>0.0224</b>	1.35 (T)	0.59
12	rs7848810	Novelty seeking	0.3585	0.35 (A)	0.38	<b>0.0396</b>	0.73 (C)	0.36
1	rs7868194	Harm avoidance	0.1634	0.62 (A)	0.45	<b>0.0126</b>	1.08 (G)	0.43
7	rs1017753	Harm avoidance	0.0897	0.74 (C)	0.43	<b>0.0257</b>	0.95 (T)	0.43
9	rs1331503	Harm avoidance	<b>0.0023</b>	1.30 (A)	0.42	0.7309	0.16 (A)	0.46
13	rs1412005	Harm avoidance	<b>0.0018</b>	1.43 (T)	0.46	0.7284	0.17 (T)	0.48
14	rs689687	Harm avoidance	<b>0.0033</b>	1.54 (C)	0.52	0.6540	0.25 (T)	0.55

SNPs with  $p$ -value  $<0.05$  in at least one analysis are in bold print.

2003), whereas PBX-HOX dimers generally have important roles in vertebrate development (Moens and Selleri, 2006). Minor allele carriers may therefore have an impaired developmental expression of *DIRAS2*. Meta-analytic treatment of the aggregated ADHD data provided further evidence especially for ACGCTT haplotype, which includes the rs1412005 T allele and spans the regulatory region of *DIRAS2*, to be associated with aADHD. We therefore hypothesize that alterations in the expressional control of *DIRAS2* underlie the ADHD association, although further studies have yet to corroborate our findings.

Evidently, association of *DIRAS2* is not specific to ADHD, but also occurs for other phenotypes such as bipolar and PDs. A cross disorder analysis for all disorders combined (aADHD, bipolar, and PD) provided an OR effect for the rs1412005 T allele of 1.13 (95% CI: 1.02–1.26,  $p=0.02$ ). Given the considerable co-morbidity of these disorders with aADHD, our findings may explain a (although presumably small) part of the genetic variance underlying these clinical observations. Clues to which neurobiological (endo-)phenotype is modulated by *DIRAS2* might be obtained from personality genetics, as nine *DIRAS2* SNPs were associated with personality domains in aADHD or PD patients. Specifically, aADHD patients carrying the rs1412005 T allele, showing meta-analytic evidence of increasing risk toward aADHD, exhibit on average 3.6 point lower *Conscientiousness* and 1.4 point higher *Harm Avoidance* scores than non-carriers (Table 6). Thus, *DIRAS2* seems to predispose to a characteristic personality profile going along with ADHD, which might best be characterized by reduced *Conscientiousness* and increased *Harm Avoidance*.

However, it has to be noted that associations were quite disparate between samples so that these data can only be considered preliminary ahead of further replication.

What are the molecular mechanisms underlying these association findings? As almost nothing is known about the function of *DIRAS2*, we can only speculate. The expression profile of *DIRAS2* is specific to the brain displaying marked expression in the prefrontal cortex, the anterior cingulate cortex and the amygdala. Although the former two structures are involved in working memory, error detection and executive control—all of which are impaired in ADHD—the latter is also a key component in fear conditioning and anxiety; dampened amygdala response might well lead to increased risk taking behavior. Although *DIRAS2*s expression pattern endorses a potential pathophysiological role in ADHD and personality, the relevant molecular cascades are elusive. Di-Ras2, the protein encoded by *DIRAS2*, belongs to the small GTPase Ras family, whose members have roles in cell morphogenesis and neurogenesis. Within the Ras family, Di-Ras2 seems to have unusual biochemical properties (Kontani *et al*, 2002). Unlike other Ras kinases, it fails to activate the MAP kinase, phosphoinositide 3-kinase or AKT pathways. To date, no effector mechanisms have been described, and due to its specific catalytic characteristics, it is even unclear whether Di-Ras2 is regulated by GTP binding at all. Highly selective expression in raphe serotonin neuron sub-populations (Wylie *et al*, 2010) points to a role in the regulation of the caudal serotonergic system; however, precise pathways again remain elusive. Despite it being a commonplace statement, in this case further studies are clearly needed to

even speculate on the neurobiological and behavioral role of *Di-ras2*.

Several caveats have to be considered in the interpretation of our data. Given the genetic effect sizes (odds ratio) estimated in the discovery sample (1020 German individuals), our replication sample (2416 individuals from IMpACT) had sufficient power to detect the effects of the rs1412005 T allele (59–100%) and the ACGCTT haplotype (88–100%). Despite this fact, there still is a chance of false-positive findings. This is relevant as most associations on the single marker level would not withstand correction for multiple testing, which becomes an even more prominent issue when examining multi-axial dimensional data such as personality traits. However, as we achieved the essential goal of targeted replication in several independent populations at least for the risk haplotype, and in conjunction with previous evidence from linkage studies and GWAS, we are confident to report a true association. As all nearby ( $\pm$  one megabase) genes are not expressed in the brain, it appears unlikely that genetic variants outside of *DIRAS2*, but in linkage disequilibrium with the scrutinized polymorphisms are pathophysiologically relevant. We therefore suspect that genetic variation within *DIRAS2*, in linkage disequilibrium with the interrogated SNPs, are the ‘true’ underlying risk alleles, a hypothesis that will have to be tested in further studies using re-sequencing approaches followed by functional studies. Finally, as we did not obtain strong positive findings from all samples, small individual sample size, background, epistatic or founder effects or even gene–environment interaction may also have a role explaining that *DIRAS2* genetic variants contribute to ADHD and related phenotypes in some, but not all populations.

In conclusion, converging evidence from several hypothesis-free and hypothesis-driven approaches suggest that *DIRAS2* is a candidate gene for ADHD and related behavioral domains. Owing to lack of data on the encoded protein, the underlying molecular mechanisms nevertheless are far from being understood, so that future functional studies will have to bridge the genotype–phenotype gap.

## ACKNOWLEDGEMENTS

This study was supported by the DFG (Grant RE1632/1-1, /1-3 and /5 to AR, KFO 125 to AR, CPJ, AW, SW, HS and KPL; SFB 581 to KPL, SFB TRR 58 to AR and KPL; RTG 1252, to AR and KPL; GR 1912/5-1, to HG), BMBF (IZKF Würzburg, 01KS9603, to KPL; IZKF N-27-N, to AR) and the EC (NEWMOOD LSHM-CT-2003-503474, to KPL). The Norwegian part of the study was supported by the Research Council of Norway and the Western Norway Regional Health Authority (Helse Vest). Financial support for the Spanish part of the study was received from ‘Instituto de Salud Carlos III-FIS, Spain’ (PI040524, PI041267), ‘Fundació La Marató de TV3’ (092330/31) and ‘Agència de Gestió d’Ajuts Universitaris i de Recerca-AGAUR’(2009SGR-00971). MR is a recipient of a ‘Ramón y Cajal’ contract from ‘Ministerio de Ciencia e Innovación’ (Spain). The Dutch part of the project was supported by the Hersenstichting Nederland (Fonds Psychische Gezondheid). SHIP is part of the Community Medicine Research net of the

University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (Grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs and the Social Ministry of the Federal State of Mecklenburg-West Pomerania. Genome-wide data have been supported by the Federal Ministry of Education and Research (grant no. 03ZIK012) and a joint grant from Siemens Healthcare, Erlangen, Germany and the Federal State of Mecklenburg-West Pomerania. The University of Greifswald is a member of the ‘Center of Knowledge Interchange’ program of the Siemens AG. We thank J Romanos, A Boreatti-Hümmer and M Heine for their dedicated assistance in patient recruitment. T Töpner, N Steigerwald, G Ortega, J Auer, C Gagel, and N Döring are credited for excellent technical assistance. We thank Mariana Nogueira and Montse Corrales for their involvement in the clinical assessment in Spain, M Dolors Castellar and others from the ‘Banc de Sang i Teixits’ (Hospital Vall d’Hebron, Barcelona) for their collaboration in the recruitment of control subjects, and Cristina Sánchez-Mora for her participation in the preparation of DNA samples from patients and controls. We thank Marije Boonstra and Marten Onnink for help with patient inclusion, as well as Marlies Naber and Angelien Heister for DNA handling and genotyping. The Dutch controls were derived from the Nijmegen Biomedical Study. Principal investigators of the Nijmegen Biomedical Study are LALM Kiemeney, M den Heijer, ALM Verbeek, DW Swinkels, and B Franke. Finally, we thank all patients, families, and controls for their participation in this study.

## DISCLOSURE

In the past 3 years, Jan K Buitelaar has been a consultant to/member of advisory board of and/or speaker for Janssen Cilag BV, Eli Lilly, Bristol-Myer Squibb, Organon/Shering Plough, UCB, Shire, Medice and Servier. Sandra Kooij has received research grants from Janssen BV and Shire, and is on the speaker’s bureau of Janssen and Eli Lilly. Hans Joergen Grabe has received speakers honoraria from Bristol-Myers Squibb, Eli Lilly, Novartis, Eisai, Wyeth, Pfizer, Boehringer Ingelheim, Servier and travel funds from Janssen-Cilag, Eli Lilly, Novartis, AstraZeneca and the SALUS-Institute for Trend-Research and Therapy Evaluation in Mental Health. Henry Völzke has received research grants by Sanofi-Aventis and the Siemens AG. Susanne Walitza has received lecture honoraria from Janssen Cilag, Lilly and AstraZeneca. Christine Freitag was on the speakers’ bureau for Novartis and Janssen-Cilag during the last 3 years. Helmut Schäfer has received a honorarium for a lecture from the European School of Oncology and has been a member of a Data Safety Monitoring Board of Daiichi Sankyo. Andreas Reif has received a research grant from Astra Zeneca. The remaining authors declare no conflict of interest.

## REFERENCES

Arbeitsgemeinschaft, für Methodik und Dokumentation in der Psychiatrie (2000). *Das AMDP-System. Manual zur Dokumentation Psychiatrischer Befunde*. Göttingen, Germany: Hogrefe.

- Asherson P, Zhou K, Anney RJ, Franke B, Buitelaar J, Ebstein R et al (2008). A high-density SNP linkage scan with 142 combined subtype ADHD sib pairs identifies linkage regions on chromosomes 9 and 16. *Mol Psychiatry* 13: 514–521.
- Becker T, Knapp M (2004). Maximum-likelihood estimation of haplotype frequencies in nuclear families. *Genet Epidemiol* 27: 21–32.
- Cloninger CR, Svrakic DM, Przybeck TR (1993). A psychobiological model of temperament and character. *Arch Gen Psychiatry* 50: 975–990.
- Costa PT, McCrae RR (1992). *Revised NEO Personality Inventory (NEO PI-R) and NEO Five Factor Inventory (NEO-FFI) Manual*. Psychological Assessment Resources: Odessa.
- Dudbridge F (2008). Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. *Hum Hered* 66: 87–98.
- Faraone SV, Biederman J, Spencer T, Wilens T, Seidman LJ, Mick E et al (2000). Attention-deficit/hyperactivity disorder in adults: an overview. *Biol Psychiatry* 48: 9–20.
- Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA et al (2005). Molecular genetics of attention-deficit/hyperactivity disorder. *Biol Psychiatry* 57: 1313–1323.
- Franke B, Neale BM, Faraone SV (2009). Genome-wide association studies in ADHD. *Hum Genet* 126: 13–50.
- Franke B, Vasquez AA, Johansson S, Hoogman M, Romanos J, Boreatti-Hummer A et al (2010). Multicenter analysis of the SLC6A3/DAT1 VNTR haplotype in persistent ADHD suggests differential involvement of the gene in childhood and persistent ADHD. *Neuropsychopharmacology* 35: 656–664.
- Grabe HJ, Volzke H, Ludemann J, Wolff B, Schwahn C, John U et al (2005). Mental and physical complaints in thyroid disorders in the general population. *Acta Psychiatr Scand* 112: 286–293.
- Halmoy A, Helleland H, Dramsdahl M, Bergsholm P, Fasmer OB, Haavik J (2010). Bipolar symptoms in adult attention-deficit/hyperactivity disorder: a cross-sectional study of 510 clinically diagnosed patients and 417 population-based controls. *J Clin Psychiatry* 71: 48–57.
- Jacob CP, Muller J, Schmidt M, Hohenberger K, Gutknecht L, Reif A et al (2005). Cluster B personality disorders are associated with allelic variation of monoamine oxidase A activity. *Neuropsychopharmacology* 30: 1711–1718.
- Jacob CP, Romanos J, Dempfle A, Heine M, Windemuth-Kieselbach C, Kruse A et al (2007). Co-morbidity of adult attention-deficit/hyperactivity disorder with focus on personality traits and related disorders in a tertiary referral center. *Eur Arch Psychiatry Clin Neurosci* 257: 309–317.
- Klassen LJ, Katzman MA, Chokka P (2010). Adult ADHD and its comorbidities, with a focus on bipolar disorder. *J Affect Disord* 124: 1–8.
- Kontani K, Tada M, Ogawa T, Okai T, Saito K, Araki Y et al (2002). Di-Ras, a distinct subgroup of ras family GTPases with unique biochemical properties. *J Biol Chem* 277: 41070–41078.
- Korner A, Geyer M, Roth M, Drapeau M, Schmutz G, Albani C et al (2008). [Personality assessment with the NEO-five-factor inventory: the 30-item-short-version (NEO-FFI-30)]. *Psychother Psychosom Med Psychol* 58: 238–245.
- Lesch KP, Selch S, Renner TJ, Jacob C, Nguyen TT, Hahn T et al (2011). Genome-wide copy number variation analysis in attention-deficit/hyperactivity disorder: association with neuropeptide Y gene dosage in an extended pedigree. *Mol Psychiatry* 16: 491–503.
- Lesch KP, Timmesfeld N, Renner TJ, Halperin R, Roser C, Nguyen TT et al (2008). Molecular genetics of adult ADHD: converging evidence from genome-wide association and extended pedigree linkage studies. *J Neural Transm* 115: 1573–1585.
- Martin ER, Monks SA, Warren LL, Kaplan NL (2000). A test for linkage and association in general pedigrees: the pedigree disequilibrium test. *Am J Hum Genet* 67: 146–154.
- Mayer CM, Cai F, Cui H, Gillespie JM, MacMillan M, Belsham DD (2003). Analysis of a repressor region in the human neuropeptide Y gene that binds Oct-1 and Pbx-1 in GT1-7 neurons. *Biochem Biophys Res Commun* 307: 847–854.
- McGuffin P, Farmer A, Harvey I (1991). A polydiagnostic application of operational criteria in studies of psychotic illness: development and reliability of the OPCRIT system. *Arch Gen Psychiatry* 48: 764–770.
- Moens CB, Selleri L (2006). Hox cofactors in vertebrate development. *Dev Biol* 291: 193–206.
- Neale BM, Medland S, Ripke S, Anney RJ, Asherson P, Buitelaar J et al (2010a). Case-control genome-wide association study of attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 49: 906–920.
- Neale BM, Medland SE, Ripke S, Asherson P, Franke B, Lesch KP et al (2010b). Meta-analysis of genome-wide association studies of attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 49: 884–897.
- Nierenberg AA, Miyahara S, Spencer T, Wisniewski SR, Otto MW, Simon N et al (2005). Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants. *Biol Psychiatry* 57: 1467–1473.
- O'Connell JR, Weeks DE (1998). PedCheck: a program for identification of genotype incompatibilities in linkage analysis. *Am J Hum Genet* 63: 259–266.
- Renner TJ, Walitza S, Dempfle A, Eckert L, Romanos M, Gerlach M et al (2008). Allelic variants of SNAP25 in a family-based sample of ADHD. *J Neural Transm* 115: 317–321.
- Romanos M, Freitag C, Jacob C, Craig DW, Dempfle A, Nguyen TT et al (2008). Genome-wide linkage analysis of ADHD using high-density SNP arrays: novel loci at 5q13.1 and 14q12. *Mol Psychiatry* 13: 522–530.
- Scholz CJ, Jacob CP, Buttenschon HN, Kittel-Schneider S, Boreatti-Hummer A, Zimmer M et al (2010). Functional variants of TSPAN8 are associated with bipolar disorder and schizophrenia. *Am J Med Genet B Neuropsychiatr Genet* 153B: 967–972.
- Seshadri S, DeStefano AL, Au R, Massaro JM, Beiser AS, Kelly-Hayes M et al (2007). Genetic correlates of brain aging on MRI and cognitive test measures: a genome-wide association and linkage analysis in the Framingham Study. *BMC Med Genet* 8(Suppl 1): S15.
- Tamam L, Karakus G, Ozpoyraz N (2008). Comorbidity of adult attention-deficit hyperactivity disorder and bipolar disorder: prevalence and clinical correlates. *Eur Arch Psychiatry Clin Neurosci* 258: 385–393.
- Williams NM, Zaharieva I, Martin A, Langley K, Mantripragada K, Fossdal R et al (2011). Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis. *Lancet* 376: 1401–1408.
- Wingo AP, Ghaemi SN (2007). A systematic review of rates and diagnostic validity of comorbid adult attention-deficit/hyperactivity disorder and bipolar disorder. *J Clin Psychiatry* 68: 1776–1784.
- Wylie CJ, Hendricks TJ, Zhang B, Wang L, Lu P, Leahy P et al (2010). Distinct transcriptomes define rostral and caudal serotonin neurons. *J Neurosci* 30: 670–684.
- Zhou K, Dempfle A, Arcos-Burgos M, Bakker SC, Banaschewski T, Biederman J et al (2008). Meta-analysis of genome-wide linkage scans of attention deficit hyperactivity disorder. *Am J Med Genet B Neuropsychiatr Genet* 147B: 1392–1398.

Supplementary Information accompanies the paper on the Neuropsychopharmacology website (<http://www.nature.com/npp>)